Regeneron Pharmaceuticals

Fierce Pharma

Regeneron ushers in new era with inaugural gene therapy approval

The FDA today approved the company’s Otarmeni, the first gene therapy for a rare genetic form of hearing loss that affects about 50 newborns per year.

Darren Incorvaia Apr 23, 2026 3:22pm

Regeneron rides into radiopharma via $2.1B biobucks Telix pact

Apr 13, 2026 7:24am

On target clinical trial success bullseye score

AstraZeneca’s COPD hits breathe life into class rocked by flops

Mar 27, 2026 5:58am

target reach ladder climb meet win beat competition

Apogee data drive hype as threat to Lilly, Sanofi becomes clear

Mar 23, 2026 9:00am

Female leg stepping on weigh scales with measuring tape

Regeneron's obesity drug shows Zepbound-like efficacy in phase 3

Mar 9, 2026 8:25am

Ipsen fails to land pivotal rare disease trial

Dec 19, 2025 3:37pm